Robert Frederich

Summary

Affiliation: Bristol-Myers Squibb
Country: USA

Publications

  1. ncbi The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial
    Robert Frederich
    Bristol Myers Squibb, Route 206 and Province Line Road, Princeton, NJ, 08543, USA
    Diabetol Metab Syndr 4:36. 2012
  2. ncbi Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
    Michael E Cobble
    Canyons Medical Center, Sandy, UT, USA
    Cardiovasc Diabetol 11:6. 2012
  3. ncbi A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes
    Robert Frederich
    Bristol Myers Squibb, Princeton, NJ 08543, USA
    Postgrad Med 122:16-27. 2010

Collaborators

Detail Information

Publications3

  1. ncbi The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial
    Robert Frederich
    Bristol Myers Squibb, Route 206 and Province Line Road, Princeton, NJ, 08543, USA
    Diabetol Metab Syndr 4:36. 2012
    ..abstract:..
  2. ncbi Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
    Michael E Cobble
    Canyons Medical Center, Sandy, UT, USA
    Cardiovasc Diabetol 11:6. 2012
    ....
  3. ncbi A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes
    Robert Frederich
    Bristol Myers Squibb, Princeton, NJ 08543, USA
    Postgrad Med 122:16-27. 2010
    ..The objective was to assess the relative risk (RR) for cardiovascular (CV) events across all 8 randomized phase 2/3 trials evaluating saxagliptin in patients with type 2 diabetes mellitus...